You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells
|
|---|---|
| Published in |
Cell Stem Cell, July 2009
|
| DOI | 10.1016/j.stem.2009.04.018 |
| Pubmed ID | |
| Authors |
Liqing Jin, Erwin M. Lee, Hayley S. Ramshaw, Samantha J. Busfield, Armando G. Peoppl, Lucy Wilkinson, Mark A. Guthridge, Daniel Thomas, Emma F. Barry, Andrew Boyd, David P. Gearing, Gino Vairo, Angel F. Lopez, John E. Dick, Richard B. Lock |
| Abstract |
Leukemia stem cells (LSCs) initiate and sustain the acute myeloid leukemia (AML) clonal hierarchy and possess biological properties rendering them resistant to conventional chemotherapy. The poor survival of AML patients raises expectations that LSC-targeted therapies might achieve durable remissions. We report that an anti-interleukin-3 (IL-3) receptor alpha chain (CD123)-neutralizing antibody (7G3) targeted AML-LSCs, impairing homing to bone marrow (BM) and activating innate immunity of nonobese diabetic/severe-combined immunodeficient (NOD/SCID) mice. 7G3 treatment profoundly reduced AML-LSC engraftment and improved mouse survival. Mice with pre-established disease showed reduced AML burden in the BM and periphery and impaired secondary transplantation upon treatment, establishing that AML-LSCs were directly targeted. 7G3 inhibited IL-3-mediated intracellular signaling of isolated AML CD34(+)CD38(-) cells in vitro and reduced their survival. These results provide clear validation for therapeutic monoclonal antibody (mAb) targeting of AML-LSCs and for translation of in vivo preclinical research findings toward a clinical application. |
Mendeley readers
The data shown below were compiled from readership statistics for 292 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 2% |
| Australia | 1 | <1% |
| Sweden | 1 | <1% |
| Netherlands | 1 | <1% |
| United Kingdom | 1 | <1% |
| India | 1 | <1% |
| Japan | 1 | <1% |
| China | 1 | <1% |
| Unknown | 279 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 68 | 23% |
| Researcher | 60 | 21% |
| Student > Bachelor | 30 | 10% |
| Student > Master | 21 | 7% |
| Professor > Associate Professor | 15 | 5% |
| Other | 49 | 17% |
| Unknown | 49 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 86 | 29% |
| Medicine and Dentistry | 63 | 22% |
| Biochemistry, Genetics and Molecular Biology | 48 | 16% |
| Immunology and Microbiology | 10 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 2% |
| Other | 29 | 10% |
| Unknown | 50 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2024.
All research outputs
#1,621,254
of 25,373,627 outputs
Outputs from Cell Stem Cell
#1,030
of 2,823 outputs
Outputs of similar age
#4,992
of 122,278 outputs
Outputs of similar age from Cell Stem Cell
#6
of 32 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,823 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 48.5. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 122,278 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.